Non-small-cell lung cancer: how to manage RET-positive disease
Targeted therapy has dramatically changed the history and outcomes of oncogene-addicted non-small-cell lung cancer (NSCLC). RET rearrangements are typically observed in about 1-2% of NSCLC, resulting in constitutive activation of downstream signalling pathways commonly involved in cell growth and su...
Saved in:
Main Authors: | Elisa Andrini (Author), Mirta Mosca (Author), Linda Galvani (Author), Francesca Sperandi (Author), Biagio Ricciuti (Author), Giulio Metro (Author), Giuseppe Lamberti (Author) |
---|---|
Format: | Book |
Published: |
BioExcel Publishing Ltd,
2022-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
by: Giulio Metro, et al.
Published: (2022) -
Non-small-cell lung cancer: how to manage EGFR-mutated disease
by: Federica Pecci, et al.
Published: (2022) -
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
by: Biagio Ricciuti, et al.
Published: (2022) -
The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks
by: Andrea De Giglio, et al.
Published: (2023) -
Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
by: Daniele Marinelli, et al.
Published: (2022)